Compare Abeona Therapeutics Inc (ABEO) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Raymond James Financial, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Raymond James Financial, Inc. trades at $165.35 (market cap $32.66B). The key difference: Raymond James Financial, Inc. is far larger — about 87.5× Abeona Therapeutics Inc's market cap, and Raymond James Financial, Inc. pays a 1.29% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | RJF | |
|---|---|---|
Market Cap | $373.32M | $32.66B |
Sector | Health | Financials |
52-Week High | $7.23 | $176.43 |
52-Week Low | $4.17 | $140.89 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Raymond James Financial (RJF) trades at $167.60, up 3.04% today, near its consensus price target of $168.00. The stock shows a bullish technical trend with strong moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth remains solid, climbing from $10.9B in 2022 to $13.84B in 2025, while net income reached $2.14B. Recent news highlights dividend declarations and record quarterly performance, reinforcing positive sentiment.
Outlook is cautiously optimistic with upside to the high target of $182.00, supported by earnings momentum and analyst coverage. Risks include rising expenses and market volatility. The stock presents a balanced opportunity for growth-oriented investors, though cost management remains a key watchpoint amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
